We observed a trend where lymphocyte populations, such as naïve CD4+ T cells (CD4+TN), CD4+ central memory (CD4+CM), CD8+ T cells, γδT cells, and B cells, were enriched in responding patients across all treatment phases, suggesting a coordinated response of these cells against tumor cells, though no statistical significance was achieved. This evidence concerns the gene CD8A and neoplasm.